首页> 美国卫生研究院文献>Journal of Translational Medicine >Development of a novel ssDNA aptamer targeting neutrophil gelatinase-associated lipocalin and its application in clinical trials
【2h】

Development of a novel ssDNA aptamer targeting neutrophil gelatinase-associated lipocalin and its application in clinical trials

机译:靶向中性粒细胞明胶酶相关脂质运载蛋白的新型ssDNA适体的开发及其在临床试验中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundNeutrophil gelatinase-associated lipocalin (NGAL) is a promising biomarker of early diagnosis and prediction for acute kidney injury (AKI). However, the current program for NGAL detection is not extensively applied in clinics due to the high expense of antibodies. Nucleic acid aptamers are single-strand DNAs or RNAs which could bind to targets with high specificity and affinity, and they have been widely used in the diagnosis and therapy for multiple diseases. It is valuable for us to develop a new method for NGAL detection using aptamers instead of antibodies to achieve increased efficiency and decreased cost.
机译:背景中性粒细胞明胶酶相关脂质运载蛋白(NGAL)是急性肾脏损伤(AKI)的早期诊断和预测的有前途的生物标志物。但是,由于抗体的高昂费用,当前用于NGAL检测的程序尚未在临床中广泛应用。核酸适体是可以以高特异性和亲和力结合靶标的单链DNA或RNA,它们已被广泛用于多种疾病的诊断和治疗。对于我们而言,开发一种使用适体而非抗体的NGAL检测新方法以提高效率和降低成本非常有价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号